High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass

scientific article

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2012-11-469130
P932PMC publication ID3624931
P698PubMed publication ID23422751
P5875ResearchGate publication ID235669201

P50authorBarbara Phillips-ButeQ115549094
P2093author name stringGrace M Lee
Thomas L Ortel
Gowthami M Arepally
Ian J Welsby
P2860cites workAntibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.Q33328813
Impact of the patient population on the risk for heparin-induced thrombocytopenia.Q33333799
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopeniaQ33348070
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopeniaQ33364229
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?Q33369345
Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgeryQ33385134
Heparin modifies the immunogenicity of positively charged proteinsQ33391937
Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesisQ33405333
Protamine-induced immune thrombocytopenia.Q33405699
Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcomeQ33407438
Heparin-induced thrombocytopenia: laboratory studiesQ33451630
Protamine-induced thrombocytopenia and leukopeniaQ33457599
Protamine: a review of its toxicityQ33457774
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgeryQ33498612
Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodiumQ33500888
High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgeryQ33503096
Allergy to protamine sulfateQ33783816
Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgeryQ34389614
Serious adverse reactions to protamine sulfate: are alternatives needed?Q34557419
Allergy to protamineQ36934496
Sperm autoantibodies as a consequence of vasectomy. II. Long-term follow-up studiesQ41156011
Risk stratification of in-hospital mortality for coronary artery bypass graft surgeryQ42679650
Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypassQ49116578
Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting.Q52996866
Protamine-induced circulatory changes.Q54474911
Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodiesQ67486376
Adverse reactions to protamine sulfate during cardiac surgery in diabetic and non-diabetic patientsQ67945798
Frequency and specificity of protamine antibodies in diabetic and control subjectsQ68149024
A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgeryQ68502476
Protamine antibody production in diabetic subjects treated with NPH insulinQ68779348
Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamineQ69490665
High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized menQ70574814
Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterizationQ70641963
Interaction of Cls̄ and Cl inactivator in the presence of heparin, dextran sulfate and protamine sulfateQ72617351
Histamine release from rat mast cells induced by protamine sulfate and polyethylene imineQ72637925
Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null alleleQ73716394
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypassQ77700079
P433issue15
P407language of work or nameEnglishQ1860
P304page(s)2828-2835
P577publication date2013-02-19
P1433published inBloodQ885070
P1476titleHigh incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass
P478volume121